Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To explore the clinical significance and diagnostic value of GP73 in early-stage primary hepatocelluar carcinoma (PHC).</p><p><b>METHODS</b>GP73 levels in 50 healthy controls, 65 cases of liver cirrhosis and 40 early stage PHC were detected by ELISA. The areas under ROC, sensitivities and specificities were also compared. The relationship between GP73 and liver function parameters was analyzed.</p><p><b>RESULTS</b>The median of serum GP73 in early PHC was 291.3 µg/L, significantly higher than that in the cirrhosis group 211.8 µg/L and in the control group 58.3 µg/L (all P<0.01). The sensitivity of GP73 (72.5%) was significantly higher than that of AFP (50.0%), P<0.05. The specificity of GP73 (70.4%) was lower than that of AFP (95.7%), P<0.05. The sensitivity and specificity in combination for diagnosis were 77.5% and 79.1%, and the area under ROC curve in the combining form was 0.838 (95% CI:0.760-0.917). In the early PHC patients, the median of GP73 in the Child C group was 365.2 µg/L, significantly higher than that in the Child B group 310.6 µg/L and Child A group 266.4 µg/L, P = 0.002. In patients with liver cirrhosis, the median of GP73 in the Child B group was 307.3 µg/L, significantly higher than that in the Child A group 176.6 µg/L, P = 0.031. The level of serum GP73 was positively correlated with ALT, AST, negatively with ABL, A/G, and with no significant correlation with AFP, TBLB, DBLB, IBLB, and GGT.</p><p><b>CONCLUSIONS</b>GP73 has a superior sensitivity in detecting early-stage PHC in liver cirrhosis patients. The sensitivity can be further increased by combining with AFP. The changes of GP73 expression may be related with the decline of liver function.</p>

Clinical epidemiological analysis of 3602 cases of primary liver cancer in Xinjiang / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the clinical epidemiological characteristics and the major causes of primary liver cancer (PLC) in Xinjiang region.</p><p><b>METHODS</b>The clinical epidemiological information on the first page of case history of 3602 PLC patients, which were diagnosed in our hospital from January 2002 to December 2010, were retrospectively reviewed and analyzed.</p><p><b>RESULTS</b>Among the 3602 cases, the men/women gender ratio was 3.72:1; The proportion of Han, Uighur, Kazakh, and other nationality (Hui, Mongolian, Manchu, Xibo nationality) was 81.95%, 9.30%, 4.14%, 2.89%, and 1.72%, respectively. The comparative difference between Uighur and Han nationalities was significant (P < 0.05). The hepatitis virus detection results showed that HBs-Ag was positive in 1680 cases (59.57%), HCV-Ab was positive in 229 cases (9.41%). Virus detection was negative in 888 patients (24.65%). The hepatitis B virus positive rate in Uygur patients was 36.13% and in Kazakh patients was 40.37%, both significantly lower than that in patients of Han nationality (63.18%, P < 0.05).</p><p><b>CONCLUSIONS</b>In Xinjiang region, the infection rate of hepatitis B virus in Uygur and Kazak people is significantly lower than that in Han people. The distribution of gender and age does not differ significantly among different nationalities, compared with those in other regions. The prevalence of primary liver cancer in Xinjiang region has certain regional characteristics and features.</p>

Expression profiles and differential diagnostic value of serum Golgi protein-73 in patients with liver cirrhosis and primary hepatic carcinoma / 中华肝脏病杂志

<p><b>OBJECTIVE</b>To investigate the expression profiles of serum Golgi protein-73 (GP73) in liver cirrhosis and primary hepatic carcinoma (PHC) and determine its clinical value for differential diagnosis.</p><p><b>METHODS</b>Serum protein expressions of GP73 and alpha-fetoprotein (AFP) were detected by enzyme-linked immunosorbent assay and chemiluminescence assay, respectively, in patients with PHC (n=80), liver cirrhosis (n=65), and healthy controls (n=50). Inter-group changes were assessed by Kruskal-Wallis test, and significance of these differences was assessed by Mann-Whitney test. A receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic efficiency and determine the cut-off values for GP73 and AFP. Sensitivity and specificity were compared by the Chi-squared test. Correlation between serum GP73 expression and clinical parameters was determined by Spearman's rank correlation analysis.</p><p><b>RESULTS</b>The PHC group showed significantly higher serum GP73 (282.0 mug/L) than the liver cirrhosis group (211.8 mug/L) and control group (58.3 mug/L) (H = 93.30, P less than 0.01). For differential diagnosis of PHC and liver cirrhosis, the cut-off value was 318.1 mug/L for GP73 and 13.4 mug/L for AFP. Sensitivity of GP73 was lower than AFP (45% (36/80) vs. 65% (52/80); X2 = 8.02, P less than 0.05). Specificity of GP73 was lower than AFP but no significance was found (83.1% (54/65) vs. 87.7% (57/65); X2=0.27, P more than 0.05). The areas under the ROC curves were not significantly different between GP73 and AFP (0.65 (95% confidence interval (CI): 0.54~0.72) vs. 0.75 (95% CI: 0.67~0.83); Z = 1.88, P more than 0.05). The area under the ROC curves increased but not significantly (0.80 (95% CI: 0.73~0.88) vs. 0.75 (95% CI: 0.67~0.83); Z=2.61, P more than 0.05). Serum GP73 was correlated with liver cirrhosis (r=0.27), vascular invasion (r=0.29), and TNM staging (r=0.27) (all P less than 0.05), but not with sex (r=0.13), age (r=0.10), enhanced AFP (> 13.4 mug/L; r=0.03), tumor size (r=0.18), or distant metastasis (r=0.04), all P less than 0.05.</p><p><b>CONCLUSION</b>Serum GP73 and AFP have comparable diagnostic efficiency, but the sensitivity of AFP is superior for differential diagnosis of liver cirrhosis and primary hepatic carcinoma. Elevated serum GP73 may be correlated with liver tumor load and aggressiveness.</p>

Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance / 南方医科大学学报

<p><b>OBJECTIVE</b>To study the plasma levels of interleukin6 (IL-6 ) and interleukin10 (IL-10) in patients with lymphoma and their association with the clinical characteristics and prognosis.</p><p><b>METHODS</b>The plasma levels of IL-6 and IL-10 were measured in 132 lymphoma patients and 132 healthy controls using enzyme-linked immunosorbent assay (ELISA).</p><p><b>RESULTS</b>The levels of plasma IL-6 and IL-10 in lymphoma patients were significantly higher than those in healthy controls (P<0.05). The plasm a levels of IL-6 were significant higher in T non-Hodgkins lymphoma (T-NHL) patients than in B non-Hodgkins lymphoma (B-NHL) patients (P<0.05), and were similar between other groups of different subtypes of lymphoma (P>0.05). Patients of Kazak nationality had a significantly higher plasma IL-6 level than those of Han and Uygur nationalities (P<0.05). The presence of B symptoms, a high risk defined by the International Prognostic Index (IPI), high levels of plasma β(2)-MG, and elevated LDH and C-reactive protein (CRP) levels were all associated with a significantly increased plasma IL-6 level (P<0.05), and patients with Ann Arbor stage III-IV disease, B symptoms, and high plasma β(2)-MG and CRP levels had significantly higher IL-10 levels (P<0.05). The plasma IL-6 and IL-10 levels were significantly lower in patients with complete remission than in those with partial remission and progressive disease and than in those without treatment (P<0.05). Plasma IL-10 was positively correlated to IL-6 and β(2)-MG levels (P<0.05).</p><p><b>CONCLUSION</b>Lymphoma patients have significantly increased plasma IL-6 and IL-10 levels with correlation to the tumor load. Plasma levels of IL-6 and IL-10 may serve as useful indicators for predicting the response to therapy and prognosis of lymphoma.</p>